For non-surgical treatments, context is the difference between useful guidance and another anxiety spiral. Pattern, density, age, family history, and treatment tolerance all matter before anyone jumps to a product or procedure.
Last fall, a buddy of mine from college, Greg, texted me a photo of the back of his head taken by his wife while he was watching football. No context. Just the picture, then: “Is this bad?” He’s 34. The crown was thinning in a textbook Norwood III vertex pattern, obvious under the overhead kitchen light his wife had been standing beneath. He’d already spent an hour Googling transplant costs in Istanbul. What he hadn’t done was try a single FDA-approved medication.
Greg’s instinct to jump straight to surgery isn’t unusual, but it’s almost always premature. Even patients who eventually get a transplant typically start with medical therapy. The boring truth is that two generic drugs, finasteride and minoxidil, still have the strongest evidence base for slowing or partially reversing pattern hair loss when started early. Everything else is either adjunctive, off-label, or surgical.
This piece covers what a thorough dermatology evaluation would cover, with one focus: the actual evidence behind those medications and the agents that supplement them.
How We Got the Norwood Scale (and Why It Still Matters)
James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences established something fundamental: men castrated before puberty didn’t develop the recession and crown thinning seen in androgenetic alopecia. Androgens were the culprit. Full stop.
O’Tar Norwood built on that work in his 1975 Southern Medical Journal paper, expanding Hamilton’s three-stage framework into the seven-stage classification system dermatologists still use. He added variant subtypes, including the Type A pattern where loss marches backward from the frontal hairline rather than following the classic bitemporal-plus-vertex route.
The combined Hamilton-Norwood scale has persisted for over 70 years, not because it’s perfect, but because it’s practical. Modern alternatives like the basic and specific (BASP) classification proposed in 2007 haven’t displaced it in routine clinical use. When your dermatologist says “Norwood III,” every other dermatologist on the planet knows exactly what that means.
The Biology: DHT, Miniaturization, and Why Your Grandfather Matters (Sort Of)
The core mechanism is dihydrotestosterone. DHT, produced from testosterone by the enzyme 5-alpha reductase, binds to androgen receptors in the dermal papilla of genetically susceptible follicles. Over successive hair cycles, it shortens the anagen (growth) phase, lengthens the telogen (resting) phase, and physically shrinks the dermal papilla. Thick terminal hairs become thin, short, unpigmented vellus hairs. Eventually they contribute nothing to visible coverage.
People love to blame the maternal grandfather. The androgen receptor gene sits on the X chromosome, so there’s some logic there. But the genetics are polygenic. Paternal loci and other autosomal contributors matter too. Family history is a clue, not a verdict.
Two drugs exploit this biology directly. Finasteride inhibits the type II isoform of 5-alpha reductase, lowering scalp DHT. Dutasteride hits both type I and type II isoforms, producing larger DHT reductions and, in head-to-head trials, larger hair density improvements. Dutasteride is approved for benign prostatic hypertrophy and used off-label for hair loss.
Getting Diagnosed Properly (Not Just Staring at Photos)
The American Academy of Dermatology’s clinical guidelines emphasize a structured workup: patient history, family history, scalp examination, trichoscopy, and selective lab testing.
History matters more than people assume. Timeline, progression pattern, medications, recent illnesses, dietary changes, crash diets. The distribution of loss helps narrow the differential between androgenetic alopecia, telogen effluvium, alopecia areata, scarring alopecias, and traction effects.
Trichoscopy (basically, dermoscopy of the scalp) reveals things the naked eye can’t. In androgenetic alopecia, you see hair shaft caliber variability of 20% or more, yellow dots from empty follicular ostia, and decreased follicular unit density in affected areas with preservation of the occipital donor zone.
Lab work is targeted, not routine. Ferritin, TSH, vitamin D, and CBC make sense when telogen effluvium is on the table or in patients with diffuse thinning. The AAD does not recommend androgen panels routinely in men with classic pattern loss. The diagnosis is clinical.
Standardized photography, front, top, sides, and back at consistent distance and lighting, allows meaningful before-and-after tracking. This is where most self-assessment falls apart. Bathroom mirror comparisons under different bulbs at different times of day are close to useless.
See also: What Is Business Banking
What Actually Works: Medications Ranked by Evidence
Treatment works best when you start early, before significant follicular loss. Here’s what the evidence supports.
Oral finasteride 1 mg daily has the deepest data. The original five-year randomized trial published in the Journal of the American Academy of Dermatology (JAAD) in 2002 demonstrated sustained improvements in hair count and patient self-assessment versus placebo. Sexual dysfunction, the side effect that dominates online forums, affects a small percentage of users in randomized trials and is generally reversible on discontinuation. The fear-to-evidence ratio on this drug is wildly skewed.
Topical minoxidil 5% twice daily is FDA-approved for over-the-counter use. The mechanism isn’t fully understood but involves potassium channel opening, vasodilation, and a direct follicular effect that prolongs anagen. Visible response typically appears at three to six months. Foam and solution are clinically equivalent, though foam causes less scalp irritation for some patients.
Low-dose oral minoxidil (0.25 to 5 mg daily) gained traction after Vañó-Galván et al. published their 2021 multicenter safety study of 1,404 patients in JAAD, demonstrating a more manageable side-effect profile at lower doses than the original cardiovascular formulation. Periorbital edema and hypertrichosis are reported, but adherence tends to be better than with twice-daily topical application. This is where the field is moving.
Platelet-rich plasma and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published several smaller randomized trials with positive but variable findings. They’re reasonable additions, not substitutes.
Hair transplantation (FUE or FUT) is the only intervention that physically redistributes follicles. It’s most appropriate when the loss pattern has stabilized, donor capacity is adequate, and expectations are realistic. For readers who want a deeper read on the staging and assessment framework referenced throughout this article, non-surgical treatments walks through the relevant clinical detail with photographic examples and stage-by-stage interpretation.
What Everything Costs
Generic oral finasteride 1 mg runs $10 to $25 per month at US pharmacies with discount cards, sometimes $5 to $15 through direct-to-consumer telehealth. Branded Propecia still costs $70 to $90 monthly with zero documented clinical advantage. That’s a remarkable markup for identical chemistry.
Generic topical minoxidil 5% costs $10 to $30 per month. Branded Rogaine roughly doubles that.
Low-dose oral minoxidil, in generic form, is often under $15 per month. The real cost driver is the prescribing visit ($50 to $150 through telehealth, or covered through insurance via a routine dermatology visit).
Hair transplantation in the US runs $4 to $10 per graft for FUE. A typical 2,500 to 3,500 graft case lands at $10,000 to $35,000. In Turkey, $2,000 to $5,000 total for similar graft counts. The price difference reflects labor cost and clinic overhead, not necessarily quality differences (though due diligence on the surgeon is non-negotiable either way).
PRP runs $500 to $1,500 per session, with most protocols recommending three to four sessions the first year plus maintenance. First-year PRP costs can equal or exceed a full year of combination medical therapy.
Insurance generally won’t cover any of this. It’s classified as cosmetic. HSAs and FSAs may cover prescribed medications and physician visits but typically exclude surgical procedures.
Lifestyle Factors: What’s Real, What’s Noise
Pattern hair loss is genetically determined. But a few lifestyle variables influence the rate of progression, and they’re documented in JAAD and the International Journal of Trichology.
Smoking accelerates loss through microvascular damage, oxidative stress, and androgen effects. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus matched nonsmokers.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) drives telogen effluvium. Iron repletion in deficient patients reduces shedding. Iron supplementation in iron-replete patients does nothing for hair density.
Vitamin D deficiency is more strongly linked to alopecia areata than to androgenetic alopecia, but JAAD reviews note that severe deficiency may contribute to hair fragility. Supplementation to normal serum levels is reasonable when deficiency is documented.
Severe acute stress can trigger telogen effluvium two to three months after the event, typically resolving within six to nine months. It doesn’t cause pattern hair loss, but it can unmask or accelerate it in susceptible individuals.
Anabolic steroid use accelerates pattern loss through supraphysiologic androgen exposure, with effects that may not fully reverse after discontinuation.
Crash diets and rapid weight loss reliably produce telogen effluvium. Modest dietary improvements beyond correcting specific deficiencies don’t produce visible hair benefits. If someone tells you a supplement stack will regrow hair, check whether they’re also selling the supplements.
When Self-Management Isn’t Enough
Several scenarios warrant in-person dermatology evaluation rather than telehealth or self-treatment:
Sudden diffuse shedding within the last six months suggests telogen effluvium, which needs workup for the precipitating cause, not pattern hair loss medications.
Patchy loss with smooth, well-circumscribed bald patches suggests alopecia areata (autoimmune, different treatment pathway entirely).
Scalp pain, burning, redness, scaling, or visible scarring raises concern for scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia). These require prompt diagnosis because follicle destruction is permanent.
Hair loss in women with menstrual irregularities, acne, or hirsutism warrants endocrine evaluation for PCOS or other androgen excess states.
Rapid progression in a young patient (more than one Norwood stage per year) deserves in-person confirmation and early intervention planning.
Failure to respond to documented, consistent use of standard medical therapy over 12 months also warrants reassessment.
The AAD’s position: any progressive hair loss that is concerning to the patient is a legitimate reason for dermatology consultation. I’d agree with that. Greg, for his part, started finasteride in November and topical minoxidil in December. He’s six months in now. No miracle, but his wife says the overhead kitchen light photo looks different. He’s no longer Googling flights to Istanbul.
FAQs
Is the Norwood scale used for women?
No. The Norwood scale is designed for male pattern hair loss. Female pattern hair loss is typically classified using the Ludwig or Savin scales, which better capture the diffuse central thinning pattern more common in women.
Should I get a hair transplant if I am in my 20s?
Experienced surgeons approach transplantation in patients in their 20s cautiously because the long-term progression pattern isn’t established yet. Medical therapy to stabilize native hair is usually prioritized first.
Can stress cause permanent hair loss?
Severe stress can trigger telogen effluvium, a temporary diffuse shedding that typically resolves within six to nine months. Stress doesn’t directly cause androgenetic alopecia, though it can unmask or accelerate underlying pattern loss in susceptible individuals.
Are hair transplants permanent?
Transplanted follicles from the genetically resistant donor zone generally retain their resistance to miniaturization and persist long-term. However, surrounding native hair may continue to thin, which is why most patients continue medical therapy after transplantation.
Can pattern hair loss be reversed?
Partially, in some patients, with early treatment. Combination finasteride and minoxidil started before substantial follicular loss has the best shot. Late-stage loss with extensive follicular dropout is generally not reversible with medical therapy alone.
Is oral minoxidil better than topical?
Low-dose oral minoxidil produces effects comparable to topical minoxidil with better adherence in many patients. The choice depends on side-effect tolerance and patient preference and should be discussed with a prescribing clinician.
How long before I see results from finasteride or minoxidil?
Most patients need three to six months of consistent use before visible changes appear, and 12 months for a full assessment of response. Stopping early is one of the most common reasons treatment “doesn’t work.”
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
